pfizer china - Search News

News

Pfizer Strikes Deal With China's 3SBio

Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

· 1d · on MSN

Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China

· 1d

Pfizer Inc. (PFE) Inks $6 Billion Cancer Drug Licensing Agreement with China’s 3SBio

BioSpace8h

Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most Favored Nation executive order; FDA Commissioner Marty Makary and CBER director ...

Fierce Biotech1d

Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

PharmExec1d

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

BioSpace1d

Pfizer’s China Deal Worth up to $6B Eclipses Peers in a Frenzied Market

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results